Australia New Zealand Gynaecological Oncology Group
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.anzgog.org.au
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Phase 2
Recruiting
- Conditions
- Ovarian CarcinosarcomaUterine Carcinosarcoma
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-02-08
- Target Recruit Count
- 30
- Registration Number
- NCT05619913
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇬🇧Imperial College London, London, United Kingdom
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Phase 2
Withdrawn
- Conditions
- Metastatic Cervical Cancer
- Interventions
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
© Copyright 2025. All Rights Reserved by MedPath